On November 12, Novanta fell 5.38% in Regular Trading, trading at $115.95, with turnover of $7.9409 million.
The move followed continued market pressure after the company reported quarterly results above expectations but issued softer near-term guidance, keeping attention on the pace of profit conversion after the Riverpoint Medical acquisition.
For the latest reported quarter, adjusted EPS was $1.05 and revenue was $305.0 million, above consensus estimates of $0.97 and $301.0 million, respectively, while revenue rose 23% year over year, including about $32.9 million from Riverpoint Medical. However, Novanta guided fourth-quarter adjusted EPS to $0.91 to $0.96 versus market expectations of $1.02, and narrowed full-year adjusted EPS to $3.66 to $3.71 from $3.68 to $3.74 previously, while full-year revenue guidance was set at $1.135 billion to $1.140 billion.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments